JP7458993B2 - Mica/b抗体および使用方法 - Google Patents

Mica/b抗体および使用方法 Download PDF

Info

Publication number
JP7458993B2
JP7458993B2 JP2020561600A JP2020561600A JP7458993B2 JP 7458993 B2 JP7458993 B2 JP 7458993B2 JP 2020561600 A JP2020561600 A JP 2020561600A JP 2020561600 A JP2020561600 A JP 2020561600A JP 7458993 B2 JP7458993 B2 JP 7458993B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511387A5 (cg-RX-API-DMAC7.html
JP2021511387A (ja
Inventor
ニール ギブソン
ジャスティン チャプマン
シン ドゥ
Original Assignee
クリナン ミカ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリナン ミカ コーポレイション filed Critical クリナン ミカ コーポレイション
Publication of JP2021511387A publication Critical patent/JP2021511387A/ja
Publication of JP2021511387A5 publication Critical patent/JP2021511387A5/ja
Priority to JP2023221150A priority Critical patent/JP2024038169A/ja
Application granted granted Critical
Publication of JP7458993B2 publication Critical patent/JP7458993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020561600A 2018-01-25 2019-01-24 Mica/b抗体および使用方法 Active JP7458993B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023221150A JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621892P 2018-01-25 2018-01-25
US62/621,892 2018-01-25
PCT/US2019/015025 WO2019147863A2 (en) 2018-01-25 2019-01-24 Mica/b antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023221150A Division JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Publications (3)

Publication Number Publication Date
JP2021511387A JP2021511387A (ja) 2021-05-06
JP2021511387A5 JP2021511387A5 (cg-RX-API-DMAC7.html) 2022-02-01
JP7458993B2 true JP7458993B2 (ja) 2024-04-01

Family

ID=67396240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561600A Active JP7458993B2 (ja) 2018-01-25 2019-01-24 Mica/b抗体および使用方法
JP2023221150A Pending JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023221150A Pending JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Country Status (10)

Country Link
US (2) US20210047417A1 (cg-RX-API-DMAC7.html)
EP (1) EP3743109A4 (cg-RX-API-DMAC7.html)
JP (2) JP7458993B2 (cg-RX-API-DMAC7.html)
KR (1) KR102731953B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566659A (cg-RX-API-DMAC7.html)
AU (1) AU2019211411B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015142A2 (cg-RX-API-DMAC7.html)
IL (1) IL276187B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007880A (cg-RX-API-DMAC7.html)
WO (1) WO2019147863A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
KR102832008B1 (ko) 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CN116547301A (zh) * 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CN119998318A (zh) * 2022-04-08 2025-05-13 D2M生物治疗有限公司 抗mica/b抗体及其用途
CN116789823A (zh) * 2023-04-04 2023-09-22 浙江大学 用于检测mica脱落片段的结构域特异性抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857116A1 (en) * 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
DK2760471T3 (en) * 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
WO2014140904A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性mic中和モノクローナル抗体
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
HRP20220890T1 (hr) * 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
EP3471761A2 (en) * 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL276187B2 (en) 2026-06-01
KR20200115545A (ko) 2020-10-07
KR102731953B1 (ko) 2024-11-20
WO2019147863A3 (en) 2019-10-24
MX2020007880A (es) 2021-05-14
EP3743109A4 (en) 2021-11-10
CA3089478A1 (en) 2019-08-01
EP3743109A2 (en) 2020-12-02
US20240067731A1 (en) 2024-02-29
IL276187B1 (en) 2026-02-01
AU2019211411A1 (en) 2020-08-20
CN112566659A (zh) 2021-03-26
RU2020128010A (ru) 2022-02-25
JP2021511387A (ja) 2021-05-06
WO2019147863A2 (en) 2019-08-01
AU2019211411B2 (en) 2025-11-27
US20210047417A1 (en) 2021-02-18
BR112020015142A2 (pt) 2021-01-05
IL276187A (en) 2020-09-30
JP2024038169A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
US20240067731A1 (en) Mica/b antibodies and methods of use
JP7734720B2 (ja) Mica/bシェディングをブロックする抗mica/b抗体および使用方法
HK1254289A1 (zh) 调控免疫反应的方法及抗体
WO2019062755A1 (en) BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
US20240026007A1 (en) Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
CN113811545B (zh) 对btn2具有特异性的抗体及其用途
CA3089478C (en) Mica/b antibodies and methods of use
CN120693178A (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
RU2821021C2 (ru) Антитела к mica/b и способы применения
RU2815101C2 (ru) Антитела против mica/b, блокирующие шеддинг mica/b, и способы их применения
KR102793781B1 (ko) Hla-g에 특이적으로 결합하는 항체 및 이의 용도
BR112021001808B1 (pt) Anticorpo monoclonal ou um fragmento de ligação ao antígeno, composição farmacêutica e uso do referido anticorpo monoclonal ou fragmento
AU2024277733A1 (en) Methods of treating cancer with anti-mica/b antibodies
CN119032103A (zh) 人源化和亲和力成熟的抗ceacam1抗体及使用方法
CN120757646A (zh) Tigit抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240319

R150 Certificate of patent or registration of utility model

Ref document number: 7458993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150